Cagrilintide, developed by Novo Nordisk under the code AM833, is a long-acting analog of amylin, the hormone the pancreas releases alongside insulin to signal fullness.
Cagrilintide dosing remains investigational. Phase 2 research tested a broad weekly dose range with escalation. This is educational source context, not a protocol or recommendation.
Lower maintenance arms in the dose-finding study.
Includes the 2.4 mg dose used in combination research.
Highest cagrilintide-only arm in the cited study; not an approved dose.
The clinical development program uses weekly administration.
The dose-finding trial included up to six weeks of dose escalation.
CagriSema schedules should not be interpreted as cagrilintide-only evidence.
Multiple doses have direct phase 2 human data, but the compound remains investigational.
Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.
Use sterile technique, refrigerate as validated, and avoid repeated freeze-thaw cycles.
Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.
What published studies and recent community write-ups report about amounts, timing and course length. 6 clinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical6 rows | |||||
| Phase 2 dose-finding trial in obesity706 adults without diabetes with a BMI of 30 or more, or 27 or more with hypertension or dyslipidemia, at 57 sites in 10 countries | 0.3, 0.6, 1.2, 2.4 or 4.5 mg maintenance, started at 0.3 mg for the lowest arm and 0.6 mg for all the others | Once weekly, stepped up every 2 weeks | Subcutaneous self-injection with a pen | 26 weeks, including up to 6 weeks of escalation, then 6 weeks of follow-up without treatmentNone during treatment; the 6-week follow-up was for washout | The Lancet (PubMed)2021 |
| Weight fell 6.0%, 6.8%, 9.1%, 9.7% and 10.8% across the five doses against 3.0% on placebo, and 4.5 mg beat daily liraglutide 3.0 mg. Everyone also received diet and activity counselling aiming at a 500 kcal daily deficit. One in ten participants stopped treatment permanently, mostly for adverse events. | |||||
| Phase 3 REDEFINE 1, cagrilintide alone arm302 of 3,417 adults with obesity or overweight plus a complication and without diabetes, in 22 countries | 2.4 mg maintenance | Once weekly | Subcutaneous | 68 weeksNone | New England Journal of Medicine2025 |
| This is the largest and longest look at cagrilintide by itself. Weight fell 11.8% at 68 weeks on the adherence-based analysis, against 16.1% for semaglutide alone, 22.7% for the combination and 2.3% for placebo. Gastrointestinal events affected 54.0% of the cagrilintide group against 39.9% on placebo, the lowest rate of any active arm. | |||||
| Phase 3 REDEFINE 1, CagriSema combination2,108 adults with obesity or overweight plus a complication, mean starting weight 106.9 kg, without diabetes | 2.4 mg of cagrilintide with 2.4 mg of semaglutide in one fixed-dose pen | Once weekly | Subcutaneous | 68 weeksNone; investigators could reduce the dose on clinical judgment | New England Journal of Medicine2025 |
| Weight fell 20.4% by intention to treat and 22.7% on the adherence-based analysis, against 3.0% and 2.3% on placebo, and 50.7% of participants with obesity ended below a BMI of 30 from a mean starting BMI of 38. Gastrointestinal events hit 79.6% of this group against 39.9% on placebo, mostly transient and mild to moderate, and the authors note that some people did well on doses below the target. | |||||
| Phase 3 REDEFINE 2 in type 2 diabetes1,206 adults with type 2 diabetes, a BMI of 27 or more and HbA1c between 7% and 10%, in 12 countries | 0.25 mg of each drug to start, then 0.5, 1.0 and 1.7 mg, reaching 2.4 mg of each after 16 weeks | Once weekly, stepped up every 4 weeks | Subcutaneous, using a dual-chamber single-use pen | 16 weeks of escalation then 52 weeks of maintenance, with 7 weeks of follow-upNone; people who could not tolerate the target dose stayed on a lower one and were asked to try escalating again at least once | New England Journal of Medicine2025 |
| This is the published escalation ladder for the combination. Weight fell 13.7% by intention to treat and 15.7% on the adherence analysis against 3.4% and 3.1% on placebo, and 73.5% reached an HbA1c of 6.5% or less compared with 15.9% on placebo. Gastrointestinal events affected 72.5% against 34.4% on placebo. | |||||
| Blood pressure analysis from REDEFINE 1Participants in REDEFINE 1 with a mean baseline systolic pressure of 127 mm Hg | 2.4 mg of cagrilintide with 2.4 mg of semaglutide | Once weekly | Subcutaneous | 68 weeksNone | Hypertension (PubMed Central)2026 |
| Systolic pressure fell 10.9 mm Hg on the adherence-based analysis, a confirmatory secondary endpoint, and the paper notes that the blood pressure change happened early in the trial rather than tracking the weight curve. These are secondary and post hoc analyses of one trial. | |||||
| Sponsor announcement of the REDEFINE 1 headline result3,417 randomized adults with obesity or overweight and at least one other condition | 2.4 mg of cagrilintide alone, 2.4 mg of semaglutide alone, or 2.4 mg of each in combination | Once weekly | Subcutaneous | 68 weeksNone | Novo Nordisk2024 |
| Novo Nordisk's December 2024 release gives the four-way comparison in one place: 22.7% for the combination, 16.1% for semaglutide alone, 11.8% for cagrilintide alone and 2.3% for placebo on the adherence analysis. It also reports that 40.4% of the combination group lost 25% or more of their body weight, against 6.0% on cagrilintide alone. | |||||
| Community-reported3 rows | |||||
| Community standalone titration ladder | 0.25 mg, then 0.5, 1.0, 1.7 and 2.4 mg | Once weekly, stepping up every 4 weeks | Subcutaneous | 16 weeks of escalation, then maintenance at 2.4 mg from week 17Hold a step longer rather than skip ahead if gut symptoms are not tolerated | Community resource2026 |
| This 2026 guide borrows the CagriSema ladder and applies it to cagrilintide on its own, while noting that the monotherapy trial actually started at 0.6 mg a week and went as high as 4.5 mg. The 0.25 mg starting figure comes from the combination pen rather than from any single-agent study. | |||||
| Low-dose community cycle | 250 mcg | Three days a week, for example Monday, Wednesday and Friday, in the morning | Subcutaneous from a 5 mg vial in 2 mL of bacteriostatic water, which is 10 units on an insulin syringe | 8 weeks on8 weeks off | Community resource2026 |
| This 2026 chart documents a pattern far below the trials: 750 mcg across a week against the 2.4 mg weekly phase 3 dose. It justifies the split schedule by the long half-life and accumulation, and states openly that the 8-week cycle is much shorter than the 26 to 68 weeks of continuous dosing the trials used. | |||||
| Syringe conversions with a provenance warning | 0.25 mg rising to 4.5 mg across 16 weeks, with unit conversions at 2.5 mg/mL and 5 mg/mL | Once weekly, stepping up every 2 weeks | Subcutaneous | About 16 weeks of escalationNot specified | Community resource2026 |
| This 2026 page publishes the arithmetic and then says plainly that the schedule itself is a construction of these protocol sites, is not taken from any trial and is documented by no published source. It identifies the 2021 Lancet trial as the only monotherapy dose-ranging evidence and sets out the 0.3 to 4.5 mg range that trial actually used. | |||||
The published combination ladder opens at 0.25 mg of each drug once weekly and holds it for four weeks. The monotherapy trial instead started at 0.6 mg a week for every arm above the lowest, so there is no single-agent precedent for a 0.25 mg start.
Three further four-week steps bring the dose to 1.7 mg, reaching the 2.4 mg maintenance dose after 16 weeks. Gastrointestinal effects cluster in this escalation window in both phase 3 trials and were mostly transient and mild to moderate.
Maintenance at 2.4 mg ran for 52 weeks to the week 68 endpoint. Participants who could not tolerate the target dose were kept in the trial on a lower one and asked to attempt escalation again at least once, and the authors suggest doses below the target may be enough for some people.
On its own, cagrilintide escalated every two weeks over up to six weeks to a maintenance dose of 0.3 to 4.5 mg, and the phase 2 trial ran 26 weeks. The single-agent arm of REDEFINE 1 held 2.4 mg for 68 weeks and produced 11.8% weight loss, roughly half the combination result.
Community charts run 8 weeks on and 8 weeks off, sometimes at 250 mcg three times a week, which adds up to well under a third of the weekly trial dose. No trial has tested any break: the phase 2 study dosed continuously for 26 weeks and the phase 3 trials for 68.
Plus 3 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Cagrilintide, developed by Novo Nordisk under the code AM833, is a long-acting analog of amylin, the hormone the pancreas releases alongside insulin to signal fullness. A C20 fatty diacid attached through a glutamate linker extends its action to about a week, so it is given as a once-weekly subcutaneous injection. On its own it produced 6.0% to 10.8% weight loss at 26 weeks in a phase 2 dose-finding trial and 11.8% at 68 weeks in a phase 3 comparison arm. Its main development path is as half of CagriSema, a fixed-dose combination with semaglutide in one pen, which produced 22.7% weight loss at 68 weeks in adults without diabetes and 15.7% in adults with type 2 diabetes on the adherence-based analysis. Neither cagrilintide alone nor CagriSema is approved, so there is no label and no approved dosing schedule.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
A phase 2 dose-finding trial compared five weekly doses with placebo and liraglutide.
Amylin pathways influence satiation and gastric emptying.
CagriSema studies combine cagrilintide with semaglutide.
Trials use escalation to reach maintenance exposures and manage tolerability.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
Weekly 0.3, 0.6, 1.2, 2.4, and 4.5 mg arms were studied for 26 weeks.
Cagrilintide 2.4 mg was studied with semaglutide 2.4 mg in type 2 diabetes.
No cagrilintide-only product has an approved public dosing label.
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Lys(C20 diacid-gamma-Glu)-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (cyclic disulfide between the cysteines at positions 3 and 8 of the amylin numbering)
Cagrilintide [INN], AM833, NNC0174-0833, UNII AO43BIF1U8, GTPL13768, EX-A10092
LDERDVMBIYGIOI-IZVMHKDJSA-N
Engineered for prolonged amylin-receptor activity
20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R,3S)-1-[[(2R)-4-amino-1-[[(2R)-1-[[2-[[(2R)-1-[[(2R)-4-amino-1-[[(2R,3S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
2 curated references, each with its journal, year and study model, plus 3 community resources reported but not linked.